Effects of U-50,488H and U-50,488H withdrawal on catecholaminergic neurons of the rat hypothalamus

Life Sciences

Volumn 66, Issue 9, 2000, Pages 803-815

  Laorden, M Luisa ^a   Milanés, M Victoria ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Corticosterone; Dopamine turnover; Hypothalamic noradrenaline turnover; Pituitary adrenal axis; U 50,488H dependence; U 50,488H tolerance

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; CORTICOSTERONE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG WITHDRAWAL; HORMONE RELEASE; HORMONE RESPONSE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LOCUS CERULEUS; NEUROSECRETORY CELL; NONHUMAN; NORADRENALIN RELEASE; RAT;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CATECHOLAMINES; CORTICOSTERONE; HYPOTHALAMUS; MALE; METHOXYHYDROXYPHENYLGLYCOL; NEURONS; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME; WEIGHT LOSS;

ANIMALIA;

EID: 0034695547     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00653-0     Document Type: Article

References (50)

1. Assenmacher, A. Szafarczyk, G. Alonso, G. Ixart and G. Barbanel, Ann.N.Y.Acad.Sci. 512 149-161 (1987).
2. B.J. Everitt, B. Meister and T. Hökfelt, Neuroendocrinology, C.B. Nemeroff (ed), 87-127, CRC Press, Boca Raton (1992).
3. P.M. Plotsky, E.T. Cunningham and E.P. Widmaier, Endocrine Rev. 10 437-458 (1989).
4. K. Itoi, T. Suda, F. Tozawa, I. Dobashi, N. Ohmori, Y. Sakai, K. Abe and H. Demura, Endocrinology 135 2177-2182 (1994).
5. M.G. Martínez-Piñero, M.V. Milanés, C. Alcaraz and M.L. Vargas, Brain Res. 668 122-128 (1994).
6. E.J. Nestler, J.Neurosci. 12 2439-2450 (1992).
7. D.W. Self and E.J. Nestler, Ann.Rev.Neurosci. 18 463-495 (1995).
8. E. Acquas, E. Carboni and G. Di Chiara, Eur.J.Pharmacol. 193 133-134 (1991).
9. Z.L. Rossetti, Y. Hmaidan and G.L. Gessa, Eur.J.Pharmacol. 221 227-234 (1992).
10. T.J. De Vries, G.H.K. Tjon Tien Ril, J.W. Van Der Laan, A.H. Mulder and A.N.M. Schoffelmeer, Life Sci. 52 1685-1693 (1993).
11. R.N. Pechnick, Ann.Rev.Pharmacol.Toxicol. 32 353-382 (1993).
12. C. Alcaraz, M.L. Vargas, T. Fuente and M.V. Milanés, J.Pharmacol.Exp.Ther. 266 1602-1606 (1993).
13. A.E. Calogero, S. Scaccianoce, N. Burrello, R. Nicolai, L.L.A. Muscolo, M.A. Kling, L. Angelucci and R. D'Agata, J.Neuroendocrinol. 8 579-585 (1996).
14. D.M. Ignar and C.M. Kuhn, J.Pharmacoi.Exp.Ther. 255 1287-1295 (1990).
15. M.L. Gonzálvez, M.V. Milanés and M.L. Vargas, Eur.J.Pharmacol. 200 155-158 (1991).
16. J.A. Martínez, M.L. Vargas, T. Fuente, J. Del Río-García and M.V. Milanés, Eur.J.Pharmacol. 182 117-123 (1990).
17. M.V. Milanés, M.L. Gonzálvez, T. Fuente and M.L. Vargas, Neuropeptides 20 95-102 (1991).
18. M.V. Milanés, M.L. Laorden, M. Chapleur-Chateau and A. Burlet, Naunyn-Schmiedeberg's Arch.Pharmacol. 356 603-610 (1997).
19. P.V. Piazza, V. Deroche, J. Deminiere, S. Maccari, M. Lemoal and H. Simon, Proc.Natl.Acad.Sci.U.S.A. 90 11738-11742 (1993).
20. R. Maldonado, L. Stinus, L.H. Gold and G.F. Koob, J.Pharmacoi.Exp.Ther. 261 669-677 (1992).
21. M.L. Gonzálvez, M.V. Milanés, M.G. Martinez-Piñero, M.T. Marín and M.L. Vargas, Brain Res. 647 199-203 (1994).
22. M.L. Vargas, M.G. Martínez-Piñero and M.V. Milanés, Naunyn-Schmiedeberg's Arch.Pharmacol. 355 501-506 (1997).
23. M.V. Milanés, M.L. Laorden, M. Chapleur-Chateau and A. Burlet, J.Pharmacoi.Exp.Ther. 285 700-706 (1998).
24. D.E. Gmerek, L.A. Dystra and J.H. Woods, J.Pharmacoi.Exp.Ther. 242 428-435 (1987).
25. S.P. Jaw, M. Makimura, K.W. Oh, B. Hoskins and I.K. Ho, Eur.J.Pharmacol. 257 153-160 (1994).
26. T. Reisine and G.I. Bell, Trends Neurosci. 16 506-509 (1993).
27. H.N. Bhargava, A. Gulati and P. Ramarao, J.Pharmacoi.Exp.Ther 251 21-26 (1989).
28. J.V. Garaulet, M.V. Milanés and M.L. Laorden, J.Pharmacol.Exp.Ther. 272 658-662 (1995).
29. M.V. Milanés and M.L. Laorden, Br.J.Pharmacol. 124 1060-1064 (1998).
30. C. Magnan, S.J. Paterson, A. Tavari and H.W. Kosterlitz, Arch.Pharmacol. 319 197-201 (1982).
31. P.E. Von Voightlander, R.A. Lahti and J.H. Ludens, J.Pharmacol.Exp.Ther. 224 7-12 (1983).
32. A.D. Blake, G. Bot and T. Reisine, Chemistry Biology 3 967-972 (1996).
33. J.C. Buckingham and T.A. Cooper, Neuroendocrinology 44 35-40 (1986).
34. M.V. Milanés, M.L. Vargas and M.I. Martín, Eur.J.Pharmacol. 271 103-109 (1994).
35. F. Artigas, M.J. Sarrias, A. Adell and E. Gelpí, Life Sci 39 1571-1578 (1986).
36. K.J. Lookingland, L.M. Ireland, J.W. Gunnet, J. Manzanares, Y. Tian and K.E. Moore, Brain Res. 559 82-88 (1991).
37. J. Raber, G.F. Koob and F.E. Bloom, J.Pharmacol.Exp.Ther. 272 815-824 (1995).
38. J. Manzanares, K.J. Lookingland and K.E. Moore, Neuroendocrinology 52 200-205 (1990).
39. I.M. Maisonneuve, S. Archer and S.D. Click, Neurosci.Lett. 181 57-60 (1994).
40. G. Di Chiara and A. Imperato, J.Pharmacoi.Exp.Ther. 244 1067-1080 (1988).
41. S. Tsagarakis, P. Navara, L.H. Rees, M. Besser and A. Grossman, Endocrinology 124 2330-2335 (1989).
42. A. Mansour, C.A. Fox, H. Akil and S.J. Watson, Trends in Neurosci. 18 22-29 (1995).
43. Z. Liposits, C. Phelix and W.K. Paull, Histochemistry 84 201-205 (1986).
44. B. Borowsky and C.M. Kuhn, Brain Res. 613 251-258 (1993).
45. L.M.J. Attila, Pharmacol.Toxicol. 64 202-209 (1989).
46. K. Nikolarakis, A. Pfeiffer, G.K. Stalla and A. Herz, Brain Res. 421 373-376 (1987).
47. E.T. Cunningham and P.E. Sawchenko, J.Comp.Neurol. 274 60-76 (1988).
48. G.F. Koob, Trends Pharmacol.Sci. 13 177-184 (1992).
49. A.H. Tang and R.J. Collins, Psychopharmacology 85 309-312 (1985).
50. M. Tallent, M.A. Dichter and T. Reisine, Neuroscience 85 873-885 (1998).